Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224071 | 0.85 | ALDH1A1 (0.46) | ALDH1A1KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL16008426 | 0.81 | TSHR (0.48) | ALDH1A1TSHRKMT2AMEN1HTT | |
| SCHEMBL15366455 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL14229022 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL14229560 | 0.76 | ACHE (0.48) | ALDH1A1KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL585472 | 0.75 | APLNR (0.56) | ALDH1A1KMT2AMEN1APLNRPOLB | |
| SCHEMBL14229564 | 0.75 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL20348021 | 0.74 | ALDH1A1 (0.43) | ALDH1A1KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL15670616 | 0.74 | KMT2A (0.49) | ALDH1A1KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL23698600 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4ETSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4055016-A1 | GPR52 MODULATOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-09-14 | — | — | EP | disclosed |
| CN-114650992-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR4 | ALDH1A1 1435/4885KDM4E 3628/4885TSHR 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.